Migraine Relief Without A Pill: Click’s FDA Cleared CT-132 Turns Smartphone Into Therapy Tool

Click’s Platform Delivers CBT-Based Treatment Through AI-Powered Mobile Engagement

 
• By Shubham Singh
CT-132 can be prescribed for patients aged 18 and older and is intended for adjunctive use alongside acute/or other preventive treatments.

More from AI

More from Medtech Insight